BR112018073553A2 - medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. - Google Patents

medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.

Info

Publication number
BR112018073553A2
BR112018073553A2 BR112018073553-1A BR112018073553A BR112018073553A2 BR 112018073553 A2 BR112018073553 A2 BR 112018073553A2 BR 112018073553 A BR112018073553 A BR 112018073553A BR 112018073553 A2 BR112018073553 A2 BR 112018073553A2
Authority
BR
Brazil
Prior art keywords
fibromyalgia
symptoms associated
pharmaceutical composition
functional symptoms
preventing
Prior art date
Application number
BR112018073553-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Jae JO Min
Ju Yi Han
Gwan Hwang Sun
Original Assignee
Sk Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co., Ltd. filed Critical Sk Biopharmaceuticals Co., Ltd.
Publication of BR112018073553A2 publication Critical patent/BR112018073553A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR112018073553-1A 2016-05-19 2017-05-18 medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. BR112018073553A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
KR10-2016-0061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
BR112018073553A2 true BR112018073553A2 (pt) 2019-03-19

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073553-1A BR112018073553A2 (pt) 2016-05-19 2017-05-18 medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.

Country Status (14)

Country Link
US (1) US10849882B2 (cg-RX-API-DMAC7.html)
EP (1) EP3459543B1 (cg-RX-API-DMAC7.html)
JP (1) JP7071287B2 (cg-RX-API-DMAC7.html)
KR (1) KR102489052B1 (cg-RX-API-DMAC7.html)
CN (1) CN109475529B (cg-RX-API-DMAC7.html)
AU (1) AU2017265839B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018073553A2 (cg-RX-API-DMAC7.html)
CA (1) CA3024286A1 (cg-RX-API-DMAC7.html)
DK (1) DK3459543T3 (cg-RX-API-DMAC7.html)
ES (1) ES2935596T3 (cg-RX-API-DMAC7.html)
MX (1) MX394245B (cg-RX-API-DMAC7.html)
PL (1) PL3459543T3 (cg-RX-API-DMAC7.html)
RU (1) RU2753525C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017200318A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391363B (es) * 2016-12-14 2025-03-21 Sk Biopharmaceuticals Co Ltd Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor.
ES3027977T3 (en) * 2017-11-14 2025-06-17 Sk Biopharmaceuticals Co Ltd Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
EP3711760B1 (en) * 2017-11-14 2024-02-14 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current
MX2020004972A (es) 2017-11-14 2020-08-24 Sk Biopharmaceuticals Co Ltd Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia.
JP7369185B2 (ja) * 2018-10-19 2023-10-25 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物の糖尿病性末梢神経障害又は化学療法剤誘発性末梢神経障害の予防、緩和又は治療のための使用
JP7724776B2 (ja) * 2019-11-22 2025-08-18 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む経口用医薬組成物及びその製造方法
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DK1406606T3 (da) * 2001-07-16 2007-03-05 Ortho Mcneil Pharm Inc Carbamatforbindelser til forebyggelse eller behandling af neuropatisk smerte og smerte forbundet med klynge- og migrænehovedpine
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
PL2445890T3 (pl) 2009-06-22 2016-02-29 Sk Biopharmaceuticals Co Ltd Sposób wytwarzania estru (R)-1-arylo-2-tetrazoliloetylowego kwasu karbaminowego
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
MX350745B (es) * 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.

Also Published As

Publication number Publication date
AU2017265839B2 (en) 2022-10-27
US10849882B2 (en) 2020-12-01
CN109475529B (zh) 2022-02-22
EP3459543A4 (en) 2020-01-15
WO2017200318A1 (ko) 2017-11-23
RU2018144785A3 (cg-RX-API-DMAC7.html) 2020-08-11
DK3459543T3 (da) 2023-02-13
EP3459543B1 (en) 2022-12-21
CN109475529A (zh) 2019-03-15
PL3459543T3 (pl) 2023-04-11
RU2753525C2 (ru) 2021-08-17
JP7071287B2 (ja) 2022-05-18
AU2017265839A1 (en) 2018-12-13
JP2019516707A (ja) 2019-06-20
EP3459543A1 (en) 2019-03-27
MX394245B (es) 2025-03-19
CA3024286A1 (en) 2017-11-23
KR102489052B1 (ko) 2023-01-16
ES2935596T3 (es) 2023-03-08
KR20170131242A (ko) 2017-11-29
US20190298694A1 (en) 2019-10-03
RU2018144785A (ru) 2020-06-19
MX2018014080A (es) 2019-04-04

Similar Documents

Publication Publication Date Title
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
WO2014144130A3 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112015026840A2 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112015012497A2 (pt) combinações farmacêuticas
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]